These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22480844)

  • 1. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
    Votanopoulos K; Ihemelandu C; Shen P; Stewart J; Russell G; Levine EA
    J Surg Res; 2013 Jan; 179(1):e133-9. PubMed ID: 22480844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
    Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
    J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
    Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
    J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
    Benzaquen E; Wang Y; Wiseman S; Rosenfeld V; Sideris L; Dubé P; Pelletier JS; Vanounou T
    Can J Surg; 2021 Mar; 64(2):E111-E118. PubMed ID: 33651573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.
    Rouers A; Laurent S; Detroz B; Meurisse M
    Acta Chir Belg; 2006; 106(3):302-6. PubMed ID: 16910003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
    Leung V; Huo YR; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
    Tabrizian P; Shrager B; Jibara G; Yang MJ; Romanoff A; Hiotis S; Sarpel U; Labow DM
    J Gastrointest Surg; 2014 May; 18(5):1024-31. PubMed ID: 24577736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
    J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
    Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors.
    Levine EA; Votanopoulos KI; Shen P; Russell G; Fenstermaker J; Mansfield P; Bartlett D; Stewart JH
    J Am Coll Surg; 2018 Apr; 226(4):434-443. PubMed ID: 29331663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
    Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
    J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
    Shimizu T; Sonoda H; Murata S; Takebayashi K; Ohta H; Miyake T; Mekata E; Shiomi H; Naka S; Tani T
    Eur J Surg Oncol; 2014 May; 40(5):521-528. PubMed ID: 24388411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.
    Glockzin G; Gerken M; Lang SA; Klinkhammer-Schalke M; Piso P; Schlitt HJ
    BMC Cancer; 2014 Nov; 14():807. PubMed ID: 25369730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.
    Moaven O; Votanopoulos KI; Shen P; Mansfield P; Bartlett DL; Russell G; McQuellon R; Stewart JH; Levine EA
    Ann Surg Oncol; 2020 Mar; 27(3):772-780. PubMed ID: 31720933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
    Sideris L; Mitchell A; Drolet P; Leblanc G; Leclerc YE; Dubé P
    Can J Surg; 2009 Apr; 52(2):135-41. PubMed ID: 19399209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
    Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
    Woeste MR; Philips P; Egger ME; Scoggins CR; McMasters KM; Martin RCG
    J Surg Oncol; 2020 Jun; 121(8):1298-1305. PubMed ID: 32239529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
    Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
    Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.